Compression behaviors of low-density porous materials under multiaxial stress conditions

In this study, uniaxial and multiaxial compression tests are conducted for studying the nonlinear deformation behaviors of a porous material during compression. In the results of uniaxial compression tests, the stress level in the plateau region is varied by the difference of direction but it is shown that this material has the character of transverse isotropicity. The multiaxial behavior of the material is also observed in this study. Equibiaxial pre-strained compression tests are adopted for the observation of the characteristics of the material. The results of these tests show that the pre-strain causes the porous material to harden, and the extent of the hardening depends on the difference of the amount of pre-strain

Compression behaviors of low-density porous materials under multiaxial stress conditions

In this study, uniaxial and multiaxial compression tests are conducted for studying the nonlinear deformation behaviors of a porous material during compression. In the results of uniaxial compression tests, the stress level in the plateau region is varied by the difference of direction but it is shown that this material has the character of transverse isotropicity. The multiaxial behavior of the material is also observed in this study. Equibiaxial pre-strained compression tests are adopted for the observation of the characteristics of the material. The results of these tests show that the pre-strain causes the porous material to harden, and the extent of the hardening depends on the difference of the amount of pre-strain

成長ホルモン治療中に全般けいれん発作を呈した2症例

我々は成長ホルモン治療中に全般けいれん発作を呈した2症例を報告する.1例はヌーナン症候群で成長ホルモン分泌不全性低身長症を有している患児で,もう1例は熱性けいれん,てんかんと非内分泌性低身長症の患児である.成長ホルモン治療とけいれん発現頻度の増加に相関を見出すことは困難である.なぜなら我々の2症例はけいれんを誘発させる要因を有している.さらに,我々はてんかん患児で,かつ成長ホルモン分泌不全性低身長症の7例を経験した.成長ホルモン治療中にけいれんの頻度,持続時間,型には変化がみられなかった.これらの結果は成長ホルモン治療がけいれんを誘発させる要因になる可能性は少ないと思われる.We report two patients experienced generalized seizures during growth hormone (GH) therapy. One patient suffered from febrile seizures, epilepsy and idiopathic short stature and other patient suffered from Noonan syndrome and GH deficiency (GHD). It is difficult to make an association between GH therapy and increased incidence of seizures, because our two cases has the potential to induce seizures. Also, we have experienced 7 cases that suffered from epilepsy and GHD and no change with regard to the incidence, duration or type of seizures during GH therapy. These results may indicate that the potential of GH to induce seizures is very low

成長ホルモン治療中に全般けいれん発作を呈した2症例

我々は成長ホルモン治療中に全般けいれん発作を呈した2症例を報告する.1例はヌーナン症候群で成長ホルモン分泌不全性低身長症を有している患児で,もう1例は熱性けいれん,てんかんと非内分泌性低身長症の患児である.成長ホルモン治療とけいれん発現頻度の増加に相関を見出すことは困難である.なぜなら我々の2症例はけいれんを誘発させる要因を有している.さらに,我々はてんかん患児で,かつ成長ホルモン分泌不全性低身長症の7例を経験した.成長ホルモン治療中にけいれんの頻度,持続時間,型には変化がみられなかった.これらの結果は成長ホルモン治療がけいれんを誘発させる要因になる可能性は少ないと思われる.We report two patients experienced generalized seizures during growth hormone (GH) therapy. One patient suffered from febrile seizures, epilepsy and idiopathic short stature and other patient suffered from Noonan syndrome and GH deficiency (GHD). It is difficult to make an association between GH therapy and increased incidence of seizures, because our two cases has the potential to induce seizures. Also, we have experienced 7 cases that suffered from epilepsy and GHD and no change with regard to the incidence, duration or type of seizures during GH therapy. These results may indicate that the potential of GH to induce seizures is very low